MCID: END057
MIFTS: 65

Endometrial Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 57 12 53 75 37 13 55 15
Endometrial Carcinoma 12 29 13 55 6 15 73
Endometrial Neoplasm 12 29 6
Malignant Neoplasm of Endometrium 12 73
Carcinoma, Endometrioid 44 73
Endometrial Neoplasms 44 73
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 57
Endometrial Carcinoma, Somatic 57
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 57
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Endometrioid Carcinoma 12
Uterine Corpus Cancer 73
Tumor of Endometrium 12
Cancer, Endometrial 40
Endometrial Ca 12
Endmc 75

Classifications:



Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot : 75 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and adenocarcinoma. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Estradiol and Estradiol valerate have been mentioned in the context of this disorder. Affiliated tissues include tissues lining the uterus, breast and lymph node, and related phenotypes are endometrial carcinoma and Decreased viability

Disease Ontology : 12 A uterine cancer that is located in tissues lining the uterus.

Wikipedia : 76 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

Description from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 34.0 KRAS MLH3 MSH3 MSH6 MUTYH
2 adenocarcinoma 32.1 CDH1 FGFR2 KRAS PTEN
3 endometrial adenocarcinoma 31.7 FGFR2 KRAS PTEN
4 uterine carcinosarcoma 31.7 CDH1 FGFR2 PTEN
5 ovarian cancer 30.9 CDH1 GAS5 HOTAIR KRAS LINC-ROR MIR200C
6 breast cancer 30.8 CASC2 CDH1 FGFR2 GAS5 HOTAIR KRAS
7 myeloma, multiple 30.7 GAS5 HOTAIR KRAS TUG1
8 pancreatic cancer 30.5 CASC2 CDH1 GAS5 HOTAIR KRAS LINC-ROR
9 melanoma 30.4 GAS5 HOTAIR LINC-ROR MIR200C PTEN
10 colorectal cancer 30.0 CASC2 CDH1 GAS5 HOTAIR KRAS LINC-ROR
11 uterine corpus endometrial carcinoma 12.1
12 female reproductive organ cancer 11.5 CDH1 KRAS MSH6 PTEN
13 colorectal adenocarcinoma 11.4 CDH1 KRAS MSH6
14 familial adenomatous polyposis 11.4 CDH1 KRAS MSH3 MSH6 MUTYH
15 respiratory system cancer 11.4 CDH1 KRAS PTEN
16 cell type cancer 11.3 CDH1 KRAS PTEN
17 gastrointestinal system benign neoplasm 11.3 CDH1 KRAS MUTYH
18 polycystic ovary syndrome 11.3
19 intestinal benign neoplasm 11.3 CDH1 KRAS MUTYH
20 lung squamous cell carcinoma 11.3 CDH1 FGFR2 KRAS PTEN TUG1
21 gastric adenocarcinoma 11.3 CDH1 FGFR2 HOTAIR KRAS PTEN
22 intrahepatic cholangiocarcinoma 11.3 CDH1 FGFR2 KRAS TUG1
23 autosomal genetic disease 11.2 MSH6 MUTYH PTEN
24 cholangiocarcinoma 11.2 CDH1 FGFR2 KRAS PTEN TUG1
25 gastrointestinal system cancer 11.2 CDH1 HOTAIR KRAS MSH6 MUTYH PTEN
26 gastric cancer, hereditary diffuse 11.2 CDH1 KRAS
27 hyperplastic polyposis syndrome 11.1 KRAS MUTYH
28 gastric leiomyoma 11.1 MSH3 MSH6
29 autosomal dominant disease 11.1 FGFR2 MLH3 MSH6
30 attenuated familial adenomatous polyposis 11.1 MSH6 MUTYH
31 squamous cell carcinoma 11.1 CDH1 FGFR2 HOTAIR KRAS PTEN TUG1
32 mutyh-associated polyposis 11.1 KRAS MUTYH
33 endometrial adenosquamous carcinoma 11.1
34 high-grade neuroendocrine carcinoma of the corpus uteri 11.1
35 thyroid cancer 11.1 CASC2 CDH1 GAS5 HOTAIR KRAS PTEN
36 triple-receptor negative breast cancer 11.0 HOTAIR LINC-ROR
37 gallbladder cancer 11.0 CDH1 HOTAIR KRAS LINC-ROR TUG1
38 bladder urothelial carcinoma 11.0 CDH1 GAS5 HOTAIR KRAS TUG1
39 endometrioid ovary carcinoma 10.9
40 lynch syndrome i 10.9
41 precocious puberty, central, 1 10.9
42 colorectal cancer, hereditary nonpolyposis, type 5 10.9
43 precocious puberty, central, 2 10.9
44 esophagus squamous cell carcinoma 10.9 HOTAIR TUG1
45 esophageal cancer 10.9 CASC2 CDH1 GAS5 HOTAIR KRAS LINC-ROR
46 prostate disease 10.9 GAS5 PTENP1
47 squamous cell carcinoma, head and neck 10.8 CDH1 GAS5 HAND2-AS1 HOTAIR PTEN
48 adenoid cystic carcinoma 10.8 CDH1 KRAS PTEN
49 glioma 10.8 CASC2 GAS5 HOTAIR PTEN
50 kidney cancer 10.8 GAS5 HOTAIR MIR200C

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Clinical features from OMIM:

608089

Human phenotypes related to Endometrial Cancer:

32
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 32 HP:0012114

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 KRAS
2 Decreased viability GR00106-A-0 9.55 KRAS
3 Decreased viability GR00221-A-1 9.55 CDH1 KRAS
4 Decreased viability GR00221-A-2 9.55 KRAS
5 Decreased viability GR00301-A 9.55 CDH1 FGFR2 KRAS MLH3
6 Decreased viability GR00342-S-1 9.55 FGFR2
7 Decreased viability GR00342-S-2 9.55 FGFR2
8 Decreased viability GR00342-S-3 9.55 FGFR2
9 Decreased viability GR00381-A-1 9.55 KRAS
10 Decreased viability GR00402-S-2 9.55 CDH1 FGFR2 KRAS MLH3

MGI Mouse Phenotypes related to Endometrial Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 CDH1 FGFR2 KRAS MSH3 MSH6 MUTYH

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
2 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 979-32-8
3
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
4
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 595-33-5 11683
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
7
Peppermint Approved, Nutraceutical Phase 4
8 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
9 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Contraceptive Agents, Male Phase 4,Phase 3,Phase 2
11 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
13 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
14 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18
Medroxyprogesterone Phase 4,Phase 3,Phase 2 520-85-4 10631
19 Appetite Stimulants Phase 4,Phase 2,Phase 3,Phase 1
20 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1
21
Megestrol Phase 4,Phase 2,Phase 3,Phase 1 3562-63-8 19090 3080587
22 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 taxane Phase 4,Phase 1,Not Applicable
24 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1,Not Applicable
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
27
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
28
Methylene blue Approved, Investigational Phase 3,Not Applicable 61-73-4
29
Levonorgestrel Approved, Investigational Phase 3,Phase 2,Not Applicable 797-63-7, 17489-40-6 13109
30
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
31
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
32
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
33
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
34
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
35
Epirubicin Approved Phase 3 56420-45-2 41867
36
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
37
Ifosfamide Approved Phase 3 3778-73-2 3690
38
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
39
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
40
Exemestane Approved, Investigational Phase 3,Phase 2,Not Applicable 107868-30-4 60198
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
42
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
43
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
46
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
48
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
49
Genistein Investigational Phase 3,Phase 1 446-72-0 5280961
50
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703

Interventional clinical trials:

(show top 50) (show all 716)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
4 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
7 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Not yet recruiting NCT03423082 Phase 4 18F fluciclovine
8 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4 transdermal Megace
9 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Unknown status NCT02762214 Phase 3
10 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
11 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
12 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
13 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
14 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
15 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
16 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
17 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
18 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
19 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
20 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
21 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
22 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
23 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
24 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
25 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
26 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
27 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
28 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
29 Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Completed NCT00490087 Phase 3
30 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
31 Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis Completed NCT00431132 Phase 3 estradiol, 10 mcg
32 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
33 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
34 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
35 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3 exemestane (Aromasin);tamoxifen + exemestane
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
38 Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00670319 Phase 3 Raloxifene HCL;Raloxifene HCL;Placebo
39 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer. Recruiting NCT03555422 Phase 3 Selinexor;Placebo
40 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
41 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
42 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Recruiting NCT02598219 Phase 3 Pre-operative SN mapping with Nanocis;Intra-operative SN mapping with patent V blue dye;Intra-operative SN mapping with indocyanin green
43 Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
44 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Recruiting NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
45 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
46 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
47 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
48 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
49 Laparoscopic Approach to Cancer of the Endometrium Active, not recruiting NCT00096408 Phase 3
50 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 29 CDH1 MLH3 MSH3 MSH6 PTEN
2 Endometrial Neoplasm 29

Anatomical Context for Endometrial Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

19
Tissues Lining The Uterus

MalaCards organs/tissues related to Endometrial Cancer:

41
Breast, Lymph Node, Uterus, Testes, Endothelial, Lung, Colon

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 2174)
# Title Authors Year
1
Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. ( 29434922 )
2018
2
Clinicopathological and prognostic significance of blood microvessel density in endometrial cancer: a meta-analysis and subgroup analysis. ( 29327157 )
2018
3
Chest wall metastasis of endometrial cancer: case report and review of the literature. ( 29433406 )
2018
4
miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development. ( 29391048 )
2018
5
Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. ( 29417286 )
2018
6
Endometrial cancer follow up; finding the confidence to let go? ( 29978539 )
2018
7
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib. ( 29963728 )
2018
8
Updates on Conservative Management of Endometrial Cancer. ( 28782618 )
2018
9
Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. ( 29426961 )
2018
10
Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer. ( 29942724 )
2018
11
Correction to: Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue. ( 29948166 )
2018
12
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. ( 29951943 )
2018
13
Endometrial cancer in the elderly: does patient age influence the choice of treatment interventions and do age-related treatment choices impact survival? ( 29975285 )
2018
14
Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies? ( 29426745 )
2018
15
Folate receptor-I+ targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. ( 29416655 )
2018
16
Contemporary approaches to High-risk, Early-Stage Serous Endometrial Cancer: Clinical Equipoise Persists. ( 29965808 )
2018
17
A small compound spindlactone A sensitizes human endometrial cancer cells to TRAIL-induced apoptosis via the inhibition of NAD(P)H dehydrogenase quinone 1. ( 29950865 )
2018
18
Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. ( 29416671 )
2018
19
Patient-initiated follow-up affects fear of recurrence and health care use: A randomized trial in early-stage endometrial cancer. ( 29978593 )
2018
20
The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )
2018
21
Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )
2018
22
Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis. ( 29441458 )
2018
23
miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. ( 29955087 )
2018
24
Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it. ( 29977988 )
2018
25
Blocking 17I^-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. ( 29144553 )
2018
26
Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. ( 29439179 )
2018
27
Skeletal Muscle Quality Beyond Average Muscle Attenuation: A Proposal of Skeletal Muscle Phenotypes to Predict Short-Term Survival in Patients With Endometrial Cancer. ( 29439176 )
2018
28
Correction to: SEOM clinical guidelines for endometrial cancer (2017). ( 29417438 )
2018
29
Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model. ( 29300901 )
2018
30
HOTTIP regulates progression of endometrial cancer via activating PI3K/AKT pathway. ( 29949146 )
2018
31
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. ( 29449189 )
2018
32
Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. ( 29338923 )
2018
33
HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. ( 29463191 )
2018
34
Association of Foxp3 promoter polymorphisms with susceptibility to endometrial cancer in the Chinese Han women. ( 29718856 )
2018
35
Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. ( 29922709 )
2018
36
Ultrasound Scoring of Endometrial Pattern for Fast-Track Identification or Exclusion of Endometrial Cancer in Women with Postmenopausal Bleeding. ( 29944932 )
2018
37
Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )
2018
38
Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate. ( 29369118 )
2018
39
Metabolomic Signature of Endometrial Cancer. ( 29235868 )
2018
40
Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway. ( 29449346 )
2018
41
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer. ( 29444159 )
2018
42
PGK1 and GRP78 overexpression correlates with clinical significance and poor prognosis in Chinese endometrial cancer patients. ( 29416645 )
2018
43
Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer. ( 29355888 )
2018
44
ATXa89LPA axis facilitates estrogena89induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway. ( 29328374 )
2018
45
A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer. ( 29024813 )
2018
46
Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes. ( 29970546 )
2018
47
The utility of measuring the apparent diffusion coefficient for peritumoral zone in assessing infiltration depth of endometrial cancer. ( 29970170 )
2018
48
PTEN negative correlates with miR-181a in tumour tissues of non-obese endometrial cancer patients. ( 29477866 )
2018
49
Management Strategies for Recurrent Endometrial Cancer. ( 29972650 )
2018
50
The role of BKCa in endometrial cancer HEC-1-B cell proliferation and migration. ( 29477869 )
2018

Variations for Endometrial Cancer

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

75
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

ClinVar genetic disease variations for Endometrial Cancer:

6
(show top 50) (show all 53)
# Gene Variation Type Significance SNP ID Assembly Location
1 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
2 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh38 Chromosome 1, 45332803: 45332803
3 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
4 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic rs36053993 GRCh38 Chromosome 1, 45331556: 45331556
5 MLH3 MLH3, 1-BP DEL, 885G deletion Pathogenic
6 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh37 Chromosome 10, 89690847: 89690847
7 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh38 Chromosome 10, 87931090: 87931090
8 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh38 Chromosome 5, 80675103: 80675103
9 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh37 Chromosome 5, 79970922: 79970922
10 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
11 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
12 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh37 Chromosome 12, 25398279: 25398279
13 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh38 Chromosome 12, 25245345: 25245345
14 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
15 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
16 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh37 Chromosome 10, 123274794: 123274794
17 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh38 Chromosome 10, 121515280: 121515280
18 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh37 Chromosome 10, 123274803: 123274803
19 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh38 Chromosome 10, 121515289: 121515289
20 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
21 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh38 Chromosome 3, 41224610: 41224610
22 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh37 Chromosome 2, 48027853: 48027853
23 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh38 Chromosome 2, 47800714: 47800714
24 MSH6 NM_000179.2(MSH6): c.10C> T (p.Gln4Ter) single nucleotide variant Pathogenic rs786201042 GRCh37 Chromosome 2, 48010382: 48010382
25 MSH6 NM_000179.2(MSH6): c.10C> T (p.Gln4Ter) single nucleotide variant Pathogenic rs786201042 GRCh38 Chromosome 2, 47783243: 47783243
26 FGFR2 NM_000141.4(FGFR2): c.1121A> G (p.Asp374Gly) single nucleotide variant Likely pathogenic rs1057520028 GRCh37 Chromosome 10, 123274797: 123274797
27 CTNNB1 NM_001904.3(CTNNB1): c.94G> A (p.Asp32Asn) single nucleotide variant Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
28 CTNNB1 NM_001904.3(CTNNB1): c.94G> A (p.Asp32Asn) single nucleotide variant Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
29 CTNNB1 NM_001904.3(CTNNB1): c.95A> T (p.Asp32Val) single nucleotide variant Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
30 CTNNB1 NM_001904.3(CTNNB1): c.95A> T (p.Asp32Val) single nucleotide variant Likely pathogenic rs121913396 GRCh38 Chromosome 3, 41224607: 41224607
31 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh37 Chromosome 10, 123247577: 123247577
32 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh38 Chromosome 10, 121488063: 121488063
33 FGFR2 NM_022970.3(FGFR2): c.1144T> C (p.Tyr382His) single nucleotide variant Likely pathogenic rs387906678 GRCh37 Chromosome 10, 123274777: 123274777
34 FGFR2 NM_022970.3(FGFR2): c.1144T> C (p.Tyr382His) single nucleotide variant Likely pathogenic rs387906678 GRCh38 Chromosome 10, 121515263: 121515263
35 FGFR2 NM_000141.4(FGFR2): c.929A> G (p.Lys310Arg) single nucleotide variant Likely pathogenic rs121913475 GRCh37 Chromosome 10, 123279503: 123279503
36 FGFR2 NM_000141.4(FGFR2): c.929A> G (p.Lys310Arg) single nucleotide variant Likely pathogenic rs121913475 GRCh38 Chromosome 10, 121519989: 121519989
37 ATR NM_001184.3(ATR): c.2320delA (p.Ile774Tyrfs) deletion not provided rs757500301 GRCh37 Chromosome 3, 142274740: 142274740
38 ATR NM_001184.3(ATR): c.2320delA (p.Ile774Tyrfs) deletion not provided rs757500301 GRCh38 Chromosome 3, 142555898: 142555898
39 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh37 Chromosome 10, 123258039: 123258039
40 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh38 Chromosome 10, 121498525: 121498525
41 FGFR2 NM_000141.4(FGFR2): c.1972A> G (p.Lys658Glu) single nucleotide variant Likely pathogenic rs1057520027 GRCh37 Chromosome 10, 123247519: 123247519
42 FGFR2 NM_000141.4(FGFR2): c.1972A> G (p.Lys658Glu) single nucleotide variant Likely pathogenic rs1057520027 GRCh38 Chromosome 10, 121488005: 121488005
43 FGFR2 NM_000141.4(FGFR2): c.1121A> G (p.Asp374Gly) single nucleotide variant Likely pathogenic rs1057520028 GRCh38 Chromosome 10, 121515283: 121515283
44 FGFR2 NM_000141.4(FGFR2): c.1974A> T (p.Lys658Asn) single nucleotide variant Likely pathogenic rs1057520029 GRCh37 Chromosome 10, 123247517: 123247517
45 FGFR2 NM_000141.4(FGFR2): c.1974A> T (p.Lys658Asn) single nucleotide variant Likely pathogenic rs1057520029 GRCh38 Chromosome 10, 121488003: 121488003
46 PIK3CA NM_006218.3(PIK3CA): c.3074C> G (p.Thr1025Ser) single nucleotide variant Likely pathogenic GRCh38 Chromosome 3, 179234231: 179234231
47 PIK3CA NM_006218.3(PIK3CA): c.3074C> G (p.Thr1025Ser) single nucleotide variant Likely pathogenic GRCh37 Chromosome 3, 178952019: 178952019
48 FGFR3; TACC3 NC_000004.12: g.1735761_1806926dup duplication Likely pathogenic GRCh37 Chromosome 4, 1737488: 1808653
49 FGFR3; TACC3 NC_000004.12: g.1735761_1806926dup duplication Likely pathogenic GRCh38 Chromosome 4, 1735761: 1806926
50 subset of 24 genes:PKD1; TSC2 NC_000016.10: g.2077605_2284389dup duplication Uncertain significance GRCh38 Chromosome 16, 2077605: 2284389

Cosmic variations for Endometrial Cancer:

9
(show top 50) (show all 4084)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6935601 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 15
2 COSM6982868 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 15
3 COSM6935600 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 15
4 COSM6845183 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2143C>T p.R715* 16:72958003-72958003 15
5 COSM6845177 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7490C>T p.S2497L 16:72795192-72795192 15
6 COSM6845174 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 15
7 COSM973503 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8152G>A p.A2718T 16:72794530-72794530 15
8 COSM6845142 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 15
9 COSM6845190 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 15
10 COSM6845133 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 15
11 COSM6845182 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3628C>T p.R1210* 16:72811940-72811940 15
12 COSM6845164 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7666G>C p.A2556P 16:72795016-72795016 15
13 COSM6845156 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 15
14 COSM6845152 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1109G>A p.G370D 16:72959037-72959037 15
15 COSM6845162 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6473G>A p.R2158Q 16:72796209-72796209 15
16 COSM973493 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9001G>T p.E3001* 16:72793681-72793681 15
17 COSM6826430 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 15
18 COSM6845155 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2725G>A p.G909S 16:72950960-72950960 15
19 COSM1233352 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 15
20 COSM6826396 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 15
21 COSM6845159 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3829G>A p.V1277M 16:72811612-72811612 15
22 COSM5563443 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6820C>T p.Q2274* 16:72795862-72795862 15
23 COSM6845186 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 15
24 COSM6984593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6046G>A p.E2016K 16:72796636-72796636 15
25 COSM973492 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 15
26 COSM6984595 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 15
27 COSM6845173 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3863C>T p.T1288M 16:72811578-72811578 15
28 COSM973535 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 15
29 COSM6982810 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4103A>G p.N1368S 16:72798579-72798579 15
30 COSM6845141 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 15
31 COSM6845171 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3115C>T p.H1039Y 16:72950570-72950570 15
32 COSM1640552 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 15
33 COSM6982809 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 15
34 COSM6984596 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1378G>A p.E460K 16:72958768-72958768 15
35 COSM6845169 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 15
36 COSM6845189 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8228A>G p.Y2743C 16:72794454-72794454 15
37 COSM6845185 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5635A>T p.K1879* 16:72797047-72797047 15
38 COSM3276999 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.359G>A p.G120E 16:72959787-72959787 15
39 COSM1379731 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.884G>A p.R295H 16:72959262-72959262 15
40 COSM3276890 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3397G>A p.E1133K 16:72889782-72889782 15
41 COSM6845179 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 15
42 COSM973560 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 15
43 COSM6845161 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 15
44 COSM6845178 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8197C>A p.R2733S 16:72794485-72794485 15
45 COSM6845188 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6058A>G p.K2020E 16:72796624-72796624 15
46 COSM6984594 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 15
47 COSM6845165 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 15
48 COSM6845127 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 15
49 COSM973483 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.10750G>A p.A3584T 16:72787526-72787526 15
50 COSM6845170 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.338C>T p.A113V 16:72959808-72959808 15

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Endometrial cancer hsa05213